Cargando…

In vitro and in vivo Activity of Combinations of Polymyxin B with Other Antimicrobials Against Carbapenem-Resistant Acinetobacter baumannii

PURPOSE: To study the in vitro and in vivo antibacterial activities of polymyxin B (PB) and other five antimicrobial agents, including imipenem (IMP), meropenem (MEM), tigecycline (TGC), sulbactam (SUL), and rifampicin (RIF), alone or in combination against carbapenem-resistant Acinetobacter baumann...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Hui, Zhu, Yunzhu, Yang, Ning, Kong, Qinxiang, Zheng, Yahong, Lv, Na, Chen, Haoran, Yue, Chengcheng, Liu, Yanyan, Li, Jiabin, Ye, Ying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8577563/ https://www.ncbi.nlm.nih.gov/pubmed/34764660 http://dx.doi.org/10.2147/IDR.S334200

Ejemplares similares

In vitro and in vivo Activity of Combinations of Polymyxin B with Other Antimicrobials Against Carbapenem-Resistant Acinetobacter baumannii [Corrigendum]
Publicado: (2021)

Development and Validation of a Model for Predicting the Risk of Death in Patients with Acinetobacter baumannii Infection: A Retrospective Study
por: Zhang, Hui, et al.
Publicado: (2020)

Combatting Planktonic and Biofilm Populations of Carbapenem-Resistant Acinetobacter baumannii with Polymyxin-Based Combinations
por: Wences, Marisol, et al.
Publicado: (2022)

In vitro activity of non-bactericidal concentrations of polymyxin B in combination with other antimicrobials against OXA-23-producing carbapenem-resistant Acinetobacter baumannii
por: Netto, Bárbara, et al.
Publicado: (2013)

PKPD Modeling of the Inoculum Effect of Acinetobacter baumannii on Polymyxin B in vivo
por: Chauzy, Alexia, et al.
Publicado: (2022)

RapidResa Polymyxin Acinetobacter NP(®) Test for Rapid Detection of Polymyxin Resistance in Acinetobacter baumannii
por: Bouvier, Maxime, et al.
Publicado: (2021)

Polymyxin B/Tigecycline Combination vs. Polymyxin B or Tigecycline Alone for the Treatment of Hospital-Acquired Pneumonia Caused by Carbapenem-Resistant Enterobacteriaceae or Carbapenem-Resistant Acinetobacter baumannii
por: Chang, Kang, et al.
Publicado: (2022)

Hetero- and adaptive resistance to polymyxin B in OXA-23-producing carbapenem-resistant Acinetobacter baumannii isolates
por: Barin, Juliana, et al.
Publicado: (2013)

In-Vitro Activity of Polymyxin B, Rifampicin, Tigecycline Alone and in Combination against Carbapenem-Resistant Acinetobacter baumannii in Singapore
por: Lim, Tze-Peng, et al.
Publicado: (2011)

Risk Factors for a Hospital-Acquired Carbapenem-Resistant Klebsiella pneumoniae Bloodstream Infection: A Five-Year Retrospective Study
por: Cao, Zubai, et al.
Publicado: (2022)

The combination effect of meropenem/sulbactam/polymyxin-B on the pharmacodynamic parameters for mutant selection windows against carbapenem-resistant Acinetobacter baumannii
por: Zhang, Jiayuan, et al.
Publicado: (2022)

Prevalence and Genetic Characterization of Carbapenem- and Polymyxin-Resistant Acinetobacter baumannii Isolated from a Tertiary Hospital in Terengganu, Malaysia
por: Lean, Soo-Sum, et al.
Publicado: (2014)

Polymyxin Resistance Among XDR ST1 Carbapenem-Resistant Acinetobacter baumannii Clone Expanding in a Teaching Hospital
por: Carrasco, Letícia Dias de Melo, et al.
Publicado: (2021)

A novel decoy strategy for polymyxin resistance in Acinetobacter baumannii
por: Park, Jaeeun, et al.
Publicado: (2021)

Clinical efficacy and safety of polymyxins based versus non-polymyxins based therapies in the infections caused by carbapenem-resistant Acinetobacter baumannii: a systematic review and meta-analysis
por: Lyu, Cheng, et al.
Publicado: (2020)

In Vitro and In Vivo Activity of AS101 against Carbapenem-Resistant Acinetobacter baumannii
por: Yang, Tsung-Ying, et al.
Publicado: (2021)

Comparative Genomics of Two ST 195 Carbapenem-Resistant Acinetobacter baumannii with Different Susceptibility to Polymyxin Revealed Underlying Resistance Mechanism
por: Lean, Soo-Sum, et al.
Publicado: (2016)

Oral doxycycline to carbapenem-resistant Acinetobacter baumannii infection as a polymyxin-sparing strategy: results from a retrospective cohort
por: Tuon, Felipe Francisco, et al.
Publicado: (2023)

Molecular mechanism of antimicrobial activity of chlorhexidine against carbapenem-resistant Acinetobacter baumannii
por: Biswas, Deepika, et al.
Publicado: (2019)

Editorial Commentary: Polymyxin-Resistant Acinetobacter baumannii: Urgent Action Needed
por: Pogue, Jason M., et al.
Publicado: (2015)

Comparison between Colistin and Polymyxin B in the Treatment of Bloodstream Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa and Acinetobacter baumannii-calcoaceticus Complex
por: Garcia, Rebeca Carvalho Lacerda, et al.
Publicado: (2023)

Carbapenem-Resistant Acinetobacter baumannii in U.S. Hospitals: Diversification of Circulating Lineages and Antimicrobial Resistance
por: Iovleva, Alina, et al.
Publicado: (2022)

Strategies for Rapid Identification of Acinetobacter baumannii Membrane Proteins and Polymyxin B’s Effects
por: Lu, Yun, et al.
Publicado: (2021)

Quantitative proteomics to study carbapenem resistance in Acinetobacter baumannii
por: Tiwari, Vishvanath, et al.
Publicado: (2014)

Carbapenem-resistant Acinetobacter baumannii outbreak at university hospital
por: Takagi, E.H., et al.
Publicado: (2009)

Fanny pack transmission of carbapenem-resistant Acinetobacter baumannii
por: DelleFave, Amber, et al.
Publicado: (2023)

Global metabolic analyses identify key differences in metabolite levels between polymyxin-susceptible and polymyxin-resistant Acinetobacter baumannii
por: Mahamad Maifiah, Mohd Hafidz, et al.
Publicado: (2016)

Comparison between bacteremia caused by carbapenem resistant Acinetobacter baumannii and Acinetobacter nosocomialis
por: Yang, Ya-Sung, et al.
Publicado: (2013)

In-Vitro Evaluation of Different Antimicrobial Combinations with and without Colistin Against Carbapenem-Resistant Acinetobacter Baumannii
por: Oliva, Alessandra, et al.
Publicado: (2019)

Ω76: A designed antimicrobial peptide to combat carbapenem- and tigecycline-resistant Acinetobacter baumannii
por: Nagarajan, Deepesh, et al.
Publicado: (2019)

Antimicrobial Peptide Cec4 Eradicates the Bacteria of Clinical Carbapenem-Resistant Acinetobacter baumannii Biofilm
por: Liu, Weiwei, et al.
Publicado: (2020)

Development of Novel Peptides for the Antimicrobial Combination Therapy against Carbapenem-Resistant Acinetobacter baumannii Infection
por: Choi, Joonhyeok, et al.
Publicado: (2021)

Polymyxins Bind to the Cell Surface of Unculturable Acinetobacter baumannii and Cause Unique Dependent Resistance
por: Zhu, Yan, et al.
Publicado: (2020)

Metabolomics revealed mechanism for the synergistic effect of sulbactam, polymyxin-B and amikacin combination against Acinetobacter baumannii
por: Zhu, Shixing, et al.
Publicado: (2023)

Molecular Epidemiology and Clone Transmission of Carbapenem-Resistant Acinetobacter baumannii in ICU Rooms
por: Zhang, Xiufeng, et al.
Publicado: (2021)

Metabolomic profiling of polymyxin-B in combination with meropenem and sulbactam against multi-drug resistant Acinetobacter baumannii
por: Zhu, Shixing, et al.
Publicado: (2022)

Molecular Epidemiology of Carbapenem Non-Susceptible Acinetobacter baumannii in France
por: Jeannot, Katy, et al.
Publicado: (2014)

Mobile genetic elements related to carbapenem resistance in Acinetobacter baumannii
por: Pagano, Mariana, et al.
Publicado: (2016)

Seasonal Occurrence and Carbapenem Susceptibility of Bovine Acinetobacter baumannii in Germany
por: Klotz, Peter, et al.
Publicado: (2019)

Heterocyclic Diaryliodonium-Based Inhibitors of Carbapenem-Resistant Acinetobacter baumannii
por: Kumari, Pooja, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_t4hoeggfda01c9ljltqvd3l7ij